Portfolio of Stem Cell Stocks
Here is a table of 10 stem cell stocks.
| 10 Stem Cell Stocks | ||
|---|---|---|
Stock Returns & Price Chart | Symbol | Recent Prices & |
| Athersys | ATHX | |
| Brainstorm Cell Therapeutics | BCLI | |
| Caladrius Biosciences | CLBS | |
| Cesca Therapeutics | KOOL | |
| Geron | GERN | |
| Neuralstem | CUR | |
| Pluristem Therapeutics | PSTI | |
| Sangamo Therapeutics | SGMO | |
| Vericel | VCEL | |
| VistaGen Therapeutics | VTGN | |
| Price data from Quandl as of most recent close. | ||
To inspect the performance of the Stem Cell Stocks portfolio, see the chart below. Portfolio values are computed using monthly closes for stocks from Quandl.The 9 stocks included in the portfolio computations are: ATHX, BCLI, CLBS, KOOL, GERN, CUR, PSTI, SGMO and VCEL. The current value of the portfolio assumes that $1,111.11 was invested (total of $10,000) in each stock at its closing monthly price for the first date shown on the portfolio value chart below. All prices are adjusted for splits and dividends. VTGN was excluded from the portfolio computations because of insufficient price data.
The current value of a $10,000 investment is $4,616. The percent return is -53.84%. The annualized return is -7.44%.
| Return Summary for Stem Cell Stocks | |
|---|---|
| Start Date | Sep-30-2009 |
| Start Investment | $10,000.00 |
| End Date | Sep-19-2019 |
| Current Value of Investment | $4,615.56 |
| Total Return | -53.84% |
| Annualized Return | -7.44% |
| Min Date | Jan-31-2017 |
| Min Price | $3,711.56 |
| Max Date | Feb-28-2014 |
| Max Price | $15,046.02 |
| # Values | 121 |
| Number Returns | 7,260 |
| Number Profitable Returns | 1,834 |
| Percent Profitable Returns | 25.26% |
| Number Unprofitable Returns | 5,426 |
| Percent Unprofitable Returns | 74.74% |
| Profitable to Unprofitable Returns Ratio | 0.34 |
NOTE: The stocks included in the tables and chart are representative of the industry. They are not recommendations.
Related Portfolios
Portfolio of Gene Editing (CRISPR) Stocks